Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) saw a significant increase in short interest in the month of October. As of October 13th, there was short interest totalling 2,119,248 shares, an increase of 38.7% from the September 29th total of 1,528,017 shares. Currently, 86.2% of the shares of the company are short sold. Based on an average trading volume of 614,085 shares, the short-interest ratio is currently 3.5 days.

Separately, Zacks Investment Research cut Ekso Bionics Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, September 6th.

In other news, insider Russ Angold sold 28,254 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $1.53, for a total transaction of $43,228.62. Following the completion of the sale, the insider now owns 250,678 shares in the company, valued at $383,537.34. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have bought 41,264 shares of company stock valued at $48,255 and have sold 259,352 shares valued at $399,373. Insiders own 7.10% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Carl Domino Inc grew its stake in Ekso Bionics Holdings by 74.7% in the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock valued at $190,000 after buying an additional 35,088 shares in the last quarter. Intellectus Partners LLC grew its stake in Ekso Bionics Holdings by 5.3% in the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares in the last quarter. National Planning Corp grew its stake in Ekso Bionics Holdings by 116.2% in the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after buying an additional 126,000 shares in the last quarter. Vanguard Group Inc. grew its stake in Ekso Bionics Holdings by 32.9% in the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares in the last quarter. Finally, Independence Advisors LLC purchased a new position in Ekso Bionics Holdings in the 2nd quarter valued at approximately $1,840,000. Institutional investors and hedge funds own 2.60% of the company’s stock.

Shares of Ekso Bionics Holdings (EKSO) opened at 1.07 on Friday. Ekso Bionics Holdings has a one year low of $0.99 and a one year high of $4.90. The stock’s 50 day moving average price is $1.19 and its 200-day moving average price is $1.73. The company’s market cap is $27.59 million.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/28/ekso-bionics-holdings-inc-ekso-short-interest-update.html.

About Ekso Bionics Holdings

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.